高剂量达卡巴嗪治疗成人晚期软组织肉瘤。欧洲癌症研究与治疗组织软组织和骨肉瘤组的一项II期研究。
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.
作者信息
Buesa J M, Mouridsen H T, van Oosterom A T, Verweij J, Wagener T, Steward W, Poveda A, Vestlev P M, Thomas D, Sylvester R
机构信息
Hospital General de Asturias, Oviedo, Spain.
出版信息
Ann Oncol. 1991 Apr;2(4):307-9. doi: 10.1093/oxfordjournals.annonc.a057942.
Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of DTIC 1.2 g/m2 infused over 20 minutes, and repeated every 3 weeks. There were 1 complete and 7 partial remissions (objective activity 18%, 95% C.I. 7%-29%), with a median duration of 8 weeks (range 5-19), with the complete remission lasting 1 yr. Hematologic toxicity was dose-limiting; W.H.O. greater than or equal to 3 values were observed for WBC in 36%, and for platelets in 26% of patients. The non-hematologic toxicity included nausea and vomiting (90%), a flu-like syndrome (49%), diarrhea (35%), pain in the infused vein (28%) and hypotensive episodes (4%). Intermittent high-dose DTIC is active in advanced soft-tissue sarcoma and should be considered for inclusion in combination regimens.
50例接受过前期化疗的晚期软组织肉瘤成年患者中，44例在接受达卡巴嗪（DTIC）治疗后可评估疗效。治疗方案为DTIC 1.2 g/m²，静脉滴注20分钟，每3周重复一次。有1例完全缓解和7例部分缓解（客观有效率18%，95%可信区间7%-29%），缓解持续时间中位数为8周（范围5-19周），完全缓解持续1年。血液学毒性为剂量限制性毒性；36%的患者白细胞和26%的患者血小板出现世界卫生组织（WHO）≥3级毒性反应。非血液学毒性包括恶心和呕吐（90%）、流感样综合征（49%）、腹泻（35%）、输注静脉疼痛（28%）和低血压发作（4%）。间歇性大剂量DTIC对晚期软组织肉瘤有活性，应考虑纳入联合治疗方案。
Zotero 插件